Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.